-
公开(公告)号：KR100291144B1
公开(公告)日：2001-05-15
申请号：KR1020000058789
申请日：2000-10-06
Applicant: 한국과학기술연구원
IPC: A61K31/70
Abstract: 본 발명은 디오스민(diosmin)을 포함하는 동맥경화증 및 고지혈증의 예방 및 치료용 조성물에 관한 것으로, 디오스민은 동물에게 투여되었을 때 동맥내피에 대식세포-지질 복합체가 침착되는 것을 강력히 억제할 뿐만 아니라, ACAT 및 HMG-CoA 환원효소의 활성을 억제하고, 혈중 콜레스테롤 및 중성지질의 농도를 감소시키므로, 동맥경화증 및 고지혈증의 예방 및 치료제로서 유용하게 사용될 수 있다.
-
2.发明公开탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는동맥경화증, 고지혈증 및 지방간의 예방 및 치료용 식품조성물 无效食品复合材料用于预防和治疗阿片样物质，高胆固醇和包括鞣制或鞣制酚醛化合物的肝硬化
公开(公告)号：KR1020010030556A
公开(公告)日：2001-04-16
申请号：KR1020000062335
申请日：2000-10-23
Applicant: 한국과학기술연구원
Abstract: PURPOSE: Food composites including tannin or tannin-derived phenolics are provided to prevent and treat arteriosclerosis, hyperlipidemia and hepatic steatosis by dosing tannin, gallic acid or/and ellagic acid. CONSTITUTION: Tannin, gallic acid or/and ellagic acid is/are added to a food or a drink to prevent and treat arteriosclerosis. Tannin(C76H52O46) is extracted from acorns, persimmons and walnut shells. Gallic acid(C7H6O5) and ellagic acid(C14H6O8) are the decomposition products of tannin and have anticancer activities. The amount of the tannin-derived phenolics is from 0.01wt.% to 20wt.% according to the weight, age, gender, health status, diet, dosage time and method, excretory rate and disease level of patients.
Abstract translation: 目的：提供包括单宁或单宁衍生物酚类的食品复合材料，以预防和治疗单宁，没食子酸或鞣花酸的动脉硬化，高脂血症和肝脂肪变性。 构成：将单宁，没食子酸或/和鞣花酸加入到食物或饮料中以预防和治疗动脉硬化。 单宁（C76H52O46）从橡子，柿子和核桃壳中提取。 没食子酸（C7H6O5）和鞣花酸（C14H6O8）是单宁的分解产物，具有抗癌活性。 根据体重，年龄，性别，健康状况，饮食，剂量时间和方法，患者的排泄率和病情水平，单宁衍生物酚类的含量为0.01重量％〜20重量％。
-
公开(公告)号：KR1020010015510A
公开(公告)日：2001-02-26
申请号：KR1020000062334
申请日：2000-10-23
Applicant: 한국과학기술연구원
IPC: A61K31/366
Abstract: PURPOSE: A composition containing tannin, gallic acid or ellagic acid is provided for preventing and treating arteriosclerosis, hyperlipemia and liver diseases. CONSTITUTION: When tannin, gallic acid or ellagic acid are administrated into an animal body, they prevent the deposition of macrophage-lipid complex within the inner surface of arterial duct, decrease the concentration of GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase), gammaGTP(gamma-glutamyl transpeptidase), and lipid in serum, and strongly inhibit the damage of liver cells and the progress of fatty liver. The composition contains an effective of ellagic acid displaying an anticancer activity, that is 0.1 mg to 500 mg/weight kg a day. The composition is preferably administrated into an animal body 5 times a day in a dosage of 1 mg to 100 mg/weight kg.
Abstract translation: 目的：提供含有单宁，没食子酸或鞣花酸的组合物，用于预防和治疗动脉硬化，高脂血症和肝脏疾病。 构成：当将单宁，没食子酸或鞣花酸施用于动物体内时，可防止巨噬细胞 - 脂质复合物在动脉管内表面沉积，降低GOT（谷氨酸 - 草酰乙酸转氨酶）浓度，GPT（谷氨酸 - 丙酮酸转氨酶），γGTP（γ-谷氨酰转肽酶）和血清中的脂质，并且强烈地抑制肝细胞的损伤和脂肪肝的进展。 组合物含有显示抗癌活性的有效的鞣花酸，即每天0.1mg至500mg /重量kg。 组合物优选以1mg至100mg / kg kg的剂量每天施用5次。
-
公开(公告)号：KR1020010015495A
公开(公告)日：2001-02-26
申请号：KR1020000058705
申请日：2000-10-06
Applicant: 한국과학기술연구원
IPC: A23L1/29
Abstract: PURPOSE: A pharmaceutical composition containing one of rutin and Quercetin or the mixture is provided to prevent and treat hyperlipidemia, arteriosclerosis and liver diseases. CONSTITUTION: The rutin is extracted from buckwheat or leaves, stems and flowers of the buckwheat by leaving the materials at a base of pH10-12 by using calcium hydroxide, neutralizing and settling the materials, or by using 20-97% alcohol or water at a high temperature and pressure. The buckwheat and the leaves, stems and flowers also can be dried and pulverized to get powdered buckwheat. The resulting buckwheat flour or buckwheat extract containing 0.01-10wt% of the rutin, quercetin or the mixture of them is added to tomato ketchup, sauce and juice, ramen, noodle, bread, cookies and cracker, soup and gravies, ground beef, or dairy products to get functional foods.
Abstract translation: 目的：提供含有芦丁和槲皮素之一或混合物的药物组合物，用于预防和治疗高脂血症，动脉硬化和肝脏疾病。 构成：通过使用氢氧化钙将材料置于pH10-12的碱性条件下，从荞麦或荞麦的荞麦或叶子，茎和花中提取芦丁，中和和沉淀材料，或通过使用20-97％的酒精或水 高温高压。 荞麦和叶子，茎和花也可以干燥和粉碎以得到荞麦粉。 将含有0.01-10重量％的芦丁，槲皮素或其混合物的荞麦面粉或荞麦提取物加入番茄酱，酱汁和果汁，拉面，面条，面包，饼干和饼干，汤和肉汁，碎牛肉或 乳制品获得功能性食品。
-
-
Patent Agency Ranking
公开(公告)号：KR100296250B1
公开(公告)日：2001-10-25
申请号：KR1019980012818
申请日：1998-04-10
Applicant: 한국과학기술연구원
IPC: A61K36/725 , A61K36/752 , A61P3/06 , A61P9/12
Abstract: PURPOSE: A composition containing a jujube extract and a tangerine pericarp extract containing naringin and hesperidin is provided which has an effect on prevention of adult diseases and cancer such as liver diseases, hypertension, arteriosclerosis, hyperlipidemia or the like when administered to animals. CONSTITUTION: This composition comprises a jujube extract and hesperidin, hesperetin, naringin, naringenin or a mixture thereof as flavonoid originated from a tangerine pericarp extract in a weight ratio of 1:0.001 to 1:0.1. For an example, 5kg jujube is extracted with 15L water at 100deg.C for 2hr two times, followed by filtering. The filtrate is then concentrated under reduced pressure to produce 2kg extract. And 500g tangerine is extracted with 5L ethanol at 60deg.C for 5 hr to produce 190g extract. The jujube extract and tangerine pericarp extract can be orally or parenterally administered at a dose of 0.1 to 5g, preferably 0.5 to 1g and 0.1 to 10g, preferably 0.5 to 2g/kg.weight.day respectively.
-
7.发明公开네오헤스페리딘디하이드로칼콘을포함하는동맥경화증,고지혈증,간질환,고혈당증의예방및치료용조성물 失效包含NEOHESPERIDIN DIHYDROCHALCONE的组合物，用于预防和治疗高脂血症，肠梗塞，肝病和高血压
公开(公告)号：KR1020000019720A
公开(公告)日：2000-04-15
申请号：KR1019980037963
申请日：1998-09-15
Applicant: 한국과학기술연구원
Abstract: PURPOSE: A pharmaceutical composition and functional food and drink comprising neohesperid in dihydrochalcone are provided, for treating and preventing hyper lipidemia, arteriosclerosis, a liver disease and hyperglycemia. CONSTITUTION: The pharmaceutical composition comprises neohesperid in dihydrochalcone ineffective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of neohesperid in dihydrochalcone. Neohesperidin dihydrochalcone reduces the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase) and a lipid in blood, inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and inhibits the damage of a liver cell and the formation of a fatty liver. Also neohesperid in dihydrochalcone strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and reduces the concentration of blood sugar.
Abstract translation: 目的：提供一种包含二氢查耳酮中新月皮的药物组合物和功能性食品和饮料，用于治疗和预防高脂血症，动脉硬化，肝脏疾病和高血糖症。 组成：药物组合物含二氢查耳酮中的新皮肤无效量; 和药学上可接受的载体。 功能性食品或饮料包含二氢查耳酮中的新鲜皮肤的0.01-20重量％，优选0.1-5重量％。 新橙皮苷二氢查耳酮降低血清GOT（谷氨酸 - 草酰乙酸转氨酶），GPT（谷氨酸 - 丙酮酸转氨酶）和血液中的脂质的浓度，抑制与生物合成相关的还原酶的HMG CoA（3-羟基-3-甲基戊二酰辅酶） 的胆固醇和ACAT（酰基CoA;胆固醇-O-酰基转移酶），其将胆固醇转化为胆固醇酯，并且抑制肝细胞的损伤和脂肪肝的形成。 二氢查耳酮中的新生皮肤也强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面，并降低血糖浓度。
-
公开(公告)号：KR1020000019716A
公开(公告)日：2000-04-15
申请号：KR1019980037958
申请日：1998-09-15
Applicant: 한국과학기술연구원
IPC: A61K31/70
CPC classification number: A61K31/34 , Y10S514/866
Abstract: PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoid compounds are provided, for descending blood sugar. CONSTITUTION: The pharmaceutical composition comprises the bioflavonoid compounds represented by the formula 1 in effective amount; and pharmaceutically acceptable carriers. In the formula 1, R¬1 represents OH, rutinosyl or rhaminosyl group, R¬2 represents H, OH or rutinosyl group, R¬3 represents H or OH group, R¬4 represents OH or method group, and X represents a single bond or a double bond. The functional food comprises 0.01-50 wt%, preferably 0.05-10 wt% of the bioflavonoid compounds. The compounds of the formula 1 descends blood sugar, and therefore can be used for treating or preventing hyperglycemia.
Abstract translation: 目的：提供包含生物类黄酮化合物的药物组合物和功能性食品，用于降血糖。 构成：药物组合物包含有效量的式1所示的生物类黄酮化合物; 和药学上可接受的载体。 在式1中，R 1表示OH，芸香酰基或脱氨基糖基，R 2表示H，OH或芸香糖基，R 3表示H或OH基，R 4表示OH或方法基，X表示单 债券或双重债券。 功能性食品包含0.01-50重量％，优选0.05-10重量％的生物类黄酮化合物。 式1的化合物降低血糖，因此可用于治疗或预防高血糖症。
-
公开(公告)号：KR100213898B1
公开(公告)日：2000-03-15
申请号：KR1019990002189
申请日：1999-01-25
Applicant: 한국과학기술연구원
IPC: A61K31/70
CPC classification number: A61K31/7048 , A23L2/52 , A23L33/105 , A61K31/352
Abstract: 본 발명은 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 함유하는 심혈관 질환 예방 및 치료제 조성물에 관한 것으로, 감귤류 과피 추출물 및 이로부터 분리 정제된 헤스페리딘 및 나린진은 HMG-CoA 환원효소의 활성을 저해하여 혈중 콜레스테롤 농도를 저하시킴으로써 심장병, 동맥경화증 등의 심혈관 질환의 예방 및 치료제로 유용하게 사용될 수 있다.
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.022 seconds)
